Home|Journals|Articles by Year|Audio Abstracts RSS - TOC

Original Article

J App Pharm Sci. 2020; 10(12): 90-97

Screening of Plectranthus amboinicus against COVID-19 — in silico approach

Meenaxi M. Maste, Akash Saxena.


The present study aimed to investigate the reported bioactives from Plectranthus amboinicus as the inhibitor of novel coronavirus (COVID-19) targets, i.e., 3CLpro, PLpro, and spike protein, via in silico molecular docking and other computational approaches. The recorded bioactives were evaluated for their druglikeness characteristics using MolSoft based on the Rule of Five and the probable targets of each compound were identified using DIGEP-Pred. The bioactives were docked against 3CLPro, PLpro, and spike protein using AutoDock 4.0. In addition, the enrichment analysis of regulated proteins was carried out using STRING. Plectranthol B scored the highest druglikeness score. Additionally, Plectranthol A and B were predicted as the lead hits based on the molecular docking study. Similarly, the combined synergy of the bioactives identified the modulation of SUMOylation of intracellular receptors and the nuclear receptor transcription pathway. Furthermore, the study revealed the utilization of the system biology approach to identify the lead molecules from P. amboinicus against COVID-19 management from the traditional medicinal system.

Key words: Coronavirus, COVID-19, Traditional medicines, Plectranthus amboinicus

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.